Tempest Therapeutics
TPST
85 hedge funds and large institutions have $149M invested in Tempest Therapeutics in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 10 reducing their positions, and 6 closing their positions.
310% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 10
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
16% more funds holding
Funds holding: 73 → 85 (+12)
36% less capital invested
Capital invested by funds: $232M → $149M (-$82.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $208K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.41M |
| 2 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
+$5.35M |
| 3 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$4.27M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$3.29M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$3.06M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.39M |
| 3 |
D.E. Shaw & Co
New York
|
-$982K |
| 4 |
GS
Gagnon Securities
New York
|
-$254K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$228K |
TPST Hedge Fund Activity: Q2 2016 in Review
85 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2016, worth a combined $149M — down 36% from $232M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TPST positions and 6 closed out — a net gain of 12 holders — while 41 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.41M. The largest seller was GMT Capital, cutting an estimated $3.06M.
- 85 institutional investors held Tempest Therapeutics (TPST) as of Q2 2016, up from 73 in Q1 2016.
- Funds reported $149M of Tempest Therapeutics stock for Q2 2016, down 36% quarter-over-quarter.
- 18 funds opened new Tempest Therapeutics positions in Q2 2016 and 6 closed out, a net change of +12 holders.
- The largest Tempest Therapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $8.41M added.
- The largest Tempest Therapeutics seller in Q2 2016 was GMT Capital, an estimated $3.06M sold.
Based on aggregated 13F filings for Q2 2016.